TYPE2DIABETES KNOWLEDGE PORTAL

Providing data and tools to promote understanding and treatment of type 2 diabetes and its complications

Custom Aggregation Test Guide

The custom aggregation tests allow you to compute gene-level genetic association scores for the gene of your choice, offering the ability to set multiple parameters for the analysis. For the type 2 diabetes phenotype, the tests are powered by individual-level data from the **AMP T2D-GENES exome sequence analysis** dataset; for all other phenotypes, the tests are powered by the **19k exome sequence analysis** dataset. See the T2DKP <u>Data</u> page for descriptions of these datasets. Note that not all variants available in the variant selector will necessarily be available in the dataset being tested, and therefore only a subset of variants will be used in the aggregation test. To protect patient confidentiality, tests may not be run on sample sets that have been filtered to include fewer than 100 individuals.

The custom aggregation tests are exploratory tools. They are intended to produce results that are broadly concordant with those from expert analyses, but results produced with these tests should not be considered definitive. Rather, they may suggest hypotheses and directions for further investigation. Additionally, results may change over time, as the software and the data are under development. We are happy to provide help in evaluating the results from this tool; please contact us at the <u>T2DKP</u> <u>helpdesk</u>.

	Custom aggregation test methods	
Method	Considerations for use	References
Additive burden test	Counts variants to generate a significance score that is proportional to the number of variants. Most powerful when risk-associated variants in a gene have the same direction of effect and when a large fraction of variants affect risk (<i>e.g.</i> , when restricting the set of variants to protein-truncating variants).	See <u>Lee et al,</u> <u>2014</u>
Collapsing burden test (aggregate count)	Test for association between the total number of rare alleles observed per individual and a trait. Most powerful when risk- associated variants in a gene have the same direction of effect and when a large fraction of variants affect risk (<i>e.g.</i> , when restricting the set of variants to protein-truncating variants).	Morris and Zeggini 2010 Software
SKAT	Variance component test. More powerful than burden tests when combining rare variants that both increase and decrease the trait. Also more powerful when only a small fraction of included variants are causal.	<u>Wu et al. 2011</u> Software
SKAT-O	Robust test that combines burden and SKAT methods via an optimal grid search. Typically more powerful than burden and SKAT separately, unless the assumptions of either test are closely matched. Computationally expensive.	Lee et al. 2013 Software
Variable threshold burden test	Runs successive collapsing burden tests across a range of minor allele frequencies, selecting the optimal statistic adaptively. P-value is calculated analytically. Most powerful when risk-associated variants in a gene have the same direction of effect and when a large fraction of variants affect risk. Computationally expensive.	Lin and Tang 2011 Software

All tests use covariates to account for population structure and potential confounders. By default, the first 4 principal components along with age and sex are used as covariates.

For more information about aggregation test methods, see "Rare-Variant Association Analysis: Study Designs and Statistical Tests", <u>Lee et al, 2014</u>.

Accessing the custom aggregation tests

To access the tests, click the "Custom aggregation tests" link on the **High-impact variants** tab of the Gene page.

located of associate predicted high-impac	n chr d wit l to ca t vari	omoso h Type ause mi Add/S	me 8 be 2 diabe issense obtract D	tween 11 tes or protei otaan on	L786246 n-truncat the Top v	2 and 118 ing muta ariants ta	328900 tions in ab.)3 I the enco	ded prote	in					
Variant ID	¢	dbSN	P ID 👙	Major 🝦 allele	Minor allele	Predict	ted ≜	Protein change	∳ p- Value	• Effec	t≑ MA	F 🗍 Ge	ne 🗍 🚺	Data set	÷] \$
1181847	8 <u>3_</u> C	<u>.</u> T	rs132	66634	с	т	misse	nse p.	R325W	9.90e- 55	0.896	0.31	SLC30A	3 DIAMANTE (European) T	2D GWAS
1181847	84_0	<u>5_A.C</u>	rs168	89462	G	A	misse	nse p.	R325Q	1.92e- 14	0.891	0.040	SLC30A	B DIAGRAM MetaboChip	
1179507	68_0	<u>5_C</u>	rs168	89283	G	с	misse	nse p.	396R	0.00198	1.45	0.21	AARD	Singapore Chinese Eye St	udy GWAS
1181700	04_0	<u>.</u> T	rs733	17647	С	т	misse	nse p.	R165C	0.00476	0.580	0.0014	SLC30A	3 ExTexT2D exome chip ana	lysis
1178790	01_0	<u>.</u>	rs168	89042	с	т	splice accep	tor		0.00980	1.21	0.0021	RAD21	ExTexT2D exome chip and	ilysis: Europeans
1178643	05_A	<u>C</u>	rs144	953114	Α	С	misse	nse p.	.451R	0.0190	1.42	NaN	RAD21	DIAMANTE (European) T	2D GWAS
1181833	28_0	<u>. A,T</u>	rs147	372406	С	Α	misse	nse p.	D295E	0.0388	0.702	0.00060	SLC30A	B ExTexT2D exome chip ana	lysis
1179548	<u>10_</u> 7	<u> </u>	rs114	091176	т	С	misse	nse p.	1135	0.0533	0.625	0.059	AARD	Singapore Chinese Eye St	udy GWAS
1181848	86 (: T	rs139	999213	C.	т	misse	nse n.	P359I	0.0592	0.203	0.0013	SI C30A	BioMe AMP T2D GWAS	
gregate	var	riant: PT	s 😧 v+ns :	1% 😡			PTV+	NSbroa	d 1% 0			PTV+N	ISstrict 😡		ρτν Θ
0 0			1.23e-	9				2.74e-9	.74e-9			0.00	0000331		0.0286
0			-0.586	6				-0.621		-0.786		0.786		-0.690	
			0.775 : -0	.397		-0.826 : -		-0.826 : -0.	416			-1.1	2 : -0.454	-1.3	31:-0.0723
ດ ຄ															

Navigating the interface

- · First, select an aggregation test method (see descriptions above).
- Next, select a phenotype to compute gene-level associations with that phenotype.
- With the "Stratify" pull-down menu, you may choose to stratify by ancestry so that results are generated separately for each ancestry group.
- Different options to further customize the test will be visible in the interface depending on which method you have chosen.

This interface allows you to set custom parar variety of aggregation tests. The analysis sec sequence analysis dataset (for type 2 diabete order to protect patient privacy, these tests of	neters and generate gene-level association scores for urely accesses individual-level data from the AMP T2L s) or from the 19k exome sequence analysis subset (fo nnly allow visualization or analysis of data from more t	his gene using a -GENES exome r other phenotypes). In nan 100 individuals.	<u>Custom aggregation</u>
Choose a method, phenotyp Aggregation method	pe, and partitioning strategy Phenotype	Stratify	
Additive burden test Collapsing burden test SKAT	Type 2 diabetes	\$ none	\$
SKAT-O Variable threshold burden test	morranecriteria		

Manage variant selection (available for all methods)

The variants available for analysis are those within the coding sequence of the gene whose page you are viewing, filtered according to the criteria in the "Available variant filter" pull-down menu:

✓	Protein-truncating + missense with MAF<1%
	Protein-truncating + possibly deleterious missense with MAF<1%
	Protein-truncating + probably deleterious missense
	Protein-truncating only

These filters were documented in <u>Fuchsberger</u>, Flannick, Teslovich, Mahajan, Agarwala, Gaulton *et al.* 2016. The genetic architecture of type 2 diabetes. Nature **536**(7614):41-7.

- "Protein-truncating + missense with MAF<1%" selects variants that are protein-truncating OR are missense AND have minor allele frequency of less than 1%. The MAF criterion is added because variants of deleterious effect are likely to occur at lower frequency.
- "Protein-truncating + possibly deleterious missense with MAF<1%" selects variants that are protein-truncating OR are missense AND are predicted to be deleterious by at least one of 5 algorithms (<u>LRT</u>, <u>MutationTaster</u>, <u>PolyPhen2-HumDiv</u>, <u>PolyPhen2-HumVar</u>, or <u>SIFT</u>) AND have minor allele frequency of less than 1%.
- "Protein-truncating + probably deleterious missense" selects variants that are protein-truncating OR are missense AND are predicted to be deleterious by all 5 algorithms (<u>LRT</u>, <u>MutationTaster</u>, <u>PolyPhen2-HumDiv</u>, <u>PolyPhen2-HumVar</u>, and <u>SIFT</u>).
- "Protein-truncating only" selects variants that would cause a truncated protein to be generated, either by creating a premature stop codon or by causing a frameshift.

You may remove specific variants from the list by un-checking the box to the left of the variant ID.

The **Minor allele frequency (MAF)** text entry box allows you to select variants whose allele frequency is below an entered value, expressed as a fraction of chromosomes that carry the allele in the sampled population. For example, an allele with a frequency of 0.2 is present on 20% of the chromosomes in the population. Entering a MAF threshold manually overrides the MAF threshold in the chosen variant filter. For example, selecting the "Protein-truncating + missense with MAF<1%" filter and then entering MAF < 0.2 will add to the table any protein-truncating or missense variants in the gene with MAF between 1% and 20%.

You may choose to apply the MAF cutoff across all samples or per ancestry. MAF may differ substantially between different ancestries. Applying the cutoff per ancestry means that variants with a MAF above the threshold in any ancestry will be excluded from the analysis. The option to apply the cutoff across all samples is also available.

Choose a collection of variants for analysis. Choose a v	ariant filter; set a MAF threshold if desired (this overrides the MAF thresholds in the variant
filters) and apply the threshold across all samples or ea	ch ancestry. Remove variants from the list using the check boxes at the left of the table.
Available variant filter:	
Protein-truncating + missense with MAF<1%	
Minor Allele Frequency:	Apply MAF across:

In the variant table, all columns except "Use" may be sorted by clicking the up and down arrows. Columns in the table include:

- **Use?** checking the box for a variant includes it in the analysis, while un-checking the box removes it.
- Variant ID The variant ID specifies the number of the chromosome on which the variant is located and its chromosomal coordinate in the human genome build <u>hg19</u>, separated by a colon. Variant IDs in the table are linked to Variant pages.
- dbSNP ID the reference SNP identifier of the variant in <u>dbSNP</u>.
- Chrom. the number of the chromosome on which the variant is located.
- Position the coordinate of the variant, from the human genome build hg19.
- MAC minor allele count; number of chromosomes in the sample set that contain the minor allele.
- **Polyphen** effect on protein structure and function predicted by <u>PolyPhen-2</u> as calculated by the <u>Variant Effect Predictor</u>: benign, possibly damaging, or probably damaging.
- **SIFT** effect on protein function predicted by <u>SIFT</u> (Sorting Intolerant from Tolerant) as calculated by the <u>Variant Effect Predictor</u>: tolerated (T) or deleterious (D).
- Protein change If the variant changes the encoded protein sequence of a gene, the change is shown in this column. The format is: "p" (for protein).(identity of the amino acid in the reference allele, in <u>single letter code</u>)(protein sequence coordinate of the altered residue) (identity of the amino acid in the variant allele, in single letter code). For example, "p.R325W" indicates that the variant changes amino acid 325 from arginine to tryptophan. An asterisk indicates a stop codon.
- **Consequence** the effect of the variant on the protein or transcript within which it lies. This is expressed using controlled vocabulary terms from the <u>Sequence Ontology</u>.

Manage varia	ant selection								
Choose a c filters) and Availal	ollection of variants for an apply the threshold acros ble variant filter:	alysis. Choose a va s all samples or ead	ariant fil ch ances	ter; set a MAF thr try. Remove varia	eshold if des ants from the	sired (this overrides tl e list using the check b	ne MAF th poxes at th	nresholds ne left of t	in the variant he table.
Protei	in-truncating + missense with	MAF<1%		\$					
Minor	Allele Frequency:			Ap	ply MAF acr	oss:			
MAF <	value			•	All samples	Each ancestry			
Use?	Variant ID	dbSNP ID	Chrom.	Position	MAC 🚔	Polyphen	SIFT 🚔	Protein change	Consequence
e	<u>8 118147571 A G</u>	rs370648372	8	118147571	3	possibly damaging	D	p.E2G	missense
•	<u>8 118147597 A C</u>		8	118147597	8	possibly damaging	D	p.N11H	missense
	<u>8 118147614 GA G</u>		8	118147614	1			p.M17X	frameshift
	<u>8 118147619 A G</u>	rs534016412	8	118147619	8	possibly damaging	т	p.Y18C	missense
V	<u>8 118147622 C T</u>	rs145638764	8	118147622	1	benign	т	p.A19V	missense
•	<u>8 118147639 T A</u>	rs573681084	8	118147639	2				splice donor
	<u>8 118159230 T C</u>	rs141876609	8	118159230	10	benign	т	p.C37R	missense
•	<u>8 118159233 C T</u>		8	118159233	2	benign	т	p.P38S	missense
•	<u>8 118159253 G T</u>	rs143592691	8	118159253	24	benign	т	p.E44D	missense
•	<u>8 118159254 C A</u>	rs148043363	8	118159254	15	benign	т	p.L45M	missense
Showing 1	to 10 of 90 entries			First Previo	ous 1	2 3 4	5	9	Next Last

Select a subset of samples based on phenotypic criteria (available for the additive and collapsing burden tests)

This step allows you to filter samples such that a custom subset is used for association analysis. Filtering the samples before performing association analysis may allow you to see effects that were not detectable in the larger sample set. If you chose to stratify by ancestry, you may set separate filters for each group on individual tabs. A checkbox allows you to filter cases and controls separately.

The graphic in this section displays other phenotypes that have been measured for your chosen sample set, with their ranges. The available phenotypes differ for each dataset-phenotype combination chosen in the initial steps. Click on a phenotype to generate a bar chart showing the values present in the sample set for that phenotype. The total number of samples is shown above the bar chart.

Select a subset of samples based on phenotypic criteria									
Samples: Filter cases and co	Samples: Filter cases and controls separately								
Each of the boxes below enable phenotype. The final subset of	es you to define a criterion for i samples used will be those that	nclusion of samples in your analysis; each criterion is specified as a filter based on a single t match all of the specified criteria; to omit a criterion leave the text box blank.							
Click on the "graph" icon near e The number of samples include	each phenotype name to view t ed, as well as the distributions,	he distribution of phenotypic values for the samples currently included in the analysis. will update whenever you modify the value in the text box.							
Click a phenotype name or set va corresponding plot.	alue for a phenotype to render	Number of samples included in analysis:11765 Trait: Systolic blood pressure							
Age 💼	< \$	-							
BMI 💼	< \$	250-							
Total cholesterol 🚞	< \$								
Diastolic blood pressure 崖	< +	200							
Systolic blood pressure 📄	< \$								
Fasting glucose 🚞	< +								
Fasting insulin 📃	< \$								
HDL cholesterol 📄	< +	100-							
LDL cholesterol 📄	< \$								
Two-hour glucose 🛅	< +	50 -							
Two-hour insulin 崖	< *								
Serum creatinine 📄	< *	0-							
Triglycerides 🗮	< *								
Ancestry 📄	All Selected (5) -								
Sex 🚞	All Selected (2) -								

To filter samples, enter a number or numbers in the box and use the pull-down menu to select samples greater than or less than the entered value, or an internal or external range of values. To specify a range, enter two values separated by commas. Filters may be applied to multiple phenotypes. If the number of filtered samples is fewer than 100, the bar graph does not display in order to protect patient privacy.

Age 📃	75	Age 📄	internal 🖨	65,75
BMI 📄	internal external			

Control for covariates (available for the additive and collapsing burden tests)

The additive and collapsing burden tests allow you to choose covariates in order to control for population structure or test whether your chosen phenotype is dependent on other phenotypes. (The covariates Principal Components 1-4, age, and sex are included by default in the other tests.)

In the additive and collapsing burden tests, Principal Components 1-4 are checked by default to control for the relatedness within ancestral groups. Additional principal components are available for some datasets, and these may be selected to control for sub-groups within ancestries.

You may also select phenotypes to be used as covariates. If you chose to stratify by ancestry, choosing covariates on the "All" tab sets them for every ancestry. You may select different covariates for each ancestry on the respective ancestry tabs.

After setting all desired parameters, compute associations by clicking the "Launch analysis" button.

Results are shown in different formats, depending on your selections in the previous steps.

- p-value is shown for each association
- odds ratio is shown for dichotomous (binary) traits
- beta (effect size) is shown for continuous traits
- · confidence interval is shown for odds ratios and effect sizes
- if a dichotomous trait was selected initially, a bar chart is displayed showing the occurrence of the variant in cases and controls
- if stratification was selected, p-value, odds ratio or effect size, and confidence interval are shown for each ancestry
- if stratification was selected, a meta-analysis across all ancestries is performed, and pvalue, odds ratio or effect size, and confidence interval are shown for the meta-analysis.

Interpreting burden test results

- The **p-value** calculated for genetic associations represents the probability that the observed frequency difference would occur by chance: the lower the p-value, the greater the statistical significance of the association.
- The odds ratio (OR) is used to represent the strength of the gene-level association with a binary disease or trait (*e.g.*, T2D, ischemic stroke, chronic kidney disease). An odds ratio near 1 indicates little or no effect on disease; odds ratios greater than one mean increased likelihood of having disease, and odds ratios less than one mean decreased likelihood of having disease. Note that the numbers of cases and controls in a dataset must be roughly equivalent in order to generate a meaningful OR.

- Effect size (beta) is analogous to the odds ratio but it can be applied to continuous traits such BMI, fasting plasma glucose level, or cholesterol level.
- The **confidence interval (CI)** represents the probability that the odds ratio or effect size falls within the given range. For example, 95% CI: (0.852 to 0.941) for an odds ratio signifies that there is a 95% chance that the OR is between 0.852 and 0.941. If the confidence interval for an OR does not include 1, that supports the possibility that there is an effect on disease risk.
- **Meta-analysis** combines the independently computed association statistics for ancestry-specific associations to generate a single measure of association across all ancestries. If all groups are relatively similar to one another, performing a meta-analysis should yield similar results to a single analysis across all samples. If there are major differences between groups—for example, if there is more severe population stratification within one group than the others—then analyzing them separately has benefits. Additional parameters may be specified for the association test in the problematic group to control for stratification, and then results may be combined with the others in the meta-analysis.